Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity

Hepatology

Volumn 42, Issue 5, 2005, Pages 1028-1036

  Rigopoulou, Eirini I ^a,b   Suri, Deepak ^a,c   Chokshi, Shilpa ^a   Mullerova, Ivana ^a,d   Rice, Steven ^a   Tedder, Richard S ^a   Williams, Roger ^a   Naoumov, Nikolai V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF THESSALY   (Greece)

^c WHITTINGTON HOSPITAL   (United Kingdom)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RECOMBINANT INTERLEUKIN 12; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; INJECTION SITE REACTION; INSOMNIA; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MALE; MONOTHERAPY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIREMIA; VIRUS INHIBITION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LAMIVUDINE; MALE; PILOT PROJECTS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES; VIREMIA; VIRUS REPLICATION;

EID: 30944449094     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20888     Document Type: Article

References (46)

1. Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
2. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
3. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-229.
4. Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. HEPATOLOGY 1997; 25:1022-1027.
5. Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R, Schraut W, et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999; 261:165-172.
6. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181:1047-1058.
7. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003:77:68-76.
8. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000;156:1117-1132.
9. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
10. Schultz U, Chisari FV. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. J Virol 1999;73:3162-3168.
11. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999:284:825-829.
12. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521.
13. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-146.
14. Naoumov NV, Rossol S. Studies of interleukin-12 in chronic hepatitis B virus infection. J Viral Hepat 1997;(4 Suppl 2):87-91.
15. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997;71:3236-3243.
16. Suri D, Schilling R, Lopes AR, Mullerova I, Colucci G, Williams R, et al. Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol 2001;35:790-797.
17. Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S, et al. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B: restoration by exogenous interleukin-12. Clin Exp Immunol 2002;130:107-114.
18. Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
19. Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000;32:317-324.
20. O'Brien CB, Moonka DK, Henzel BS, Caufield M, DeBruin MF. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. Am J Gastroenterol 2001;96:2473-2479.
21. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614-624.
22. Lau G, Piratvisuth T, Luo KX, Marcellin P, Thongasawt S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
23. Janssen HL, van ZM, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365: 123-129.
24. Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. HEPATOLOGY 2003;37:1368-1374.
25. Vingerhoets J, Michielsen P, Vanham G, Bosmans E, Paulij W, Ramon A, et al. HBV-specific lymphoproliferative and cytokine responses in patients with chronic hepatitis B. J Hepatol 1998;28:8-16.
26. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysts of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-5719.
27. Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 1997;3:80-83.
28. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999;163:4481-4488.
29. Nabors GS, Afonso LC, Farrell JP, Scott P. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc Natl Acad Sci U S A 1995;92:3142-3146.
30. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998;160:5428-5435.
31. Mohan K, Sam H, Stevenson MM. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 1999;67:513-519.
32. Paganin C, Frank I, Trinchieri G. Priming for high interferon-gamma production induced by interleukin-12 in both CD4+ and CD8+ T cell clones from HIV-infected patients. J Clin Invest 1995;96:1677-1682.
33. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, et al. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 2002;16:1147-1154.
34. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997;99:3025-3033.
35. Yang J, Murphy TL, Ouyang W, Murphy KM. Induction of interferon-gamma production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activation. Eur J Immunol 1999;29:548-555.
36. Lau JY, Lai CL, Wu PC, Chung HT, Lok AS, Lin HJ. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J Med Virol 1991;34:184-187.
37. Artillo S, Pastore G, Alberti A, Milella M, Santantonio T, Fattovich G, et al. Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. J Med Virol 1998;54:167-172.
38. Lu M, Lohrengel B, Hilken G, Kemper T, Roggendorf M. Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes. J Virol 2002;76:58-67
39. Fiedler M, Rodicker F, Salucci V, Lu M, Aurisicchio L, Dahmen U, et al. Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J Virol 2004;78:10111-10121.
40. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;02:968-975.
41. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003;39:595-605.
42. Mizukoshi E, Sidney J, Livingston B, Ghany M, Hoofnagle JH, Sette A, et al. Cellular immune responses to the hepatitis B virus polymerase. J Immunol 2004;173:5863-5871.
43. Marines G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. HEPATOLOGY 1996;24:991-995.
44. Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. Dendritic cells efficiently induce protective antiviral immunity. J Virol 1998;72:3812-3818.
45. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-1365.
46. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362:1375-1377.